Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
NO DIFFERENT TREATMENT POLICY FOR TESTICULAR GERM CELL TUMORS (GCT) IN PATIENTS (PTS) WITH HIV INFECTION (MEETING ABSTRACT)
Proc Annu Meet Am Soc Clin Oncol; 11:A19 1992. Unique Identifier : AIDSLINE ICDB/92680750 Monfardini S; Crosato IM; Tumolo S; Vaccher E; Marini B; Repetto F; Pizzocaro G; Tirelli U; GICAT (Italian Cooperative Group on AIDS and Tumors), Centro di; Riferimento Oncologico, Aviano, Italy
Abstract:
Between November 1986 and November 1991, 21 cases of GCT were observed by the GICAT. Eleven pts had seminoma (SGCT) and 10 nonseminoma (NSGCT). Fifteen were IVDUs, 3 homosexuals, 1 IVDU + homosexual, 1 hemophiliac and 1 with unknown risk. At diagnosis 1 pt had AIDS, 5 pts ARC, 4 PGL and the other cases were asymptomatic. The median number of CD4+ was 127/mm3 for SGCT and 332/mm3 for NSGCT. Eight of 10 pts with Stage I and II SGCT were treated with infradiaphragmatic irradiation, while 2 refused therapy. Five of 8 pts are presently alive in CR with median duration of 24 mo, 2 died of AIDS and 1 was lost to follow-up. One pt with advanced disease treated with cisplatin, VP-16 and bleomycin (PEB) achieved a CR and died of AIDS after 12 mo. Out of 10 pts with NSGCT, 2 cases with Stage I refused therapy and were lost to follow-up. Of 2 other pts with Stage II, one underwent retroperitoneal lymph node dissection, while the other after diagnosis was lost to follow-up. Five pts with advanced disease treated with PEB for 3-4 cycles achieved a CR (median duration 34 mo). One of these pts relapsed after 5 mo and died of progressive disease. A PR was obtained in a pt with PVB. PEB was overall well tolerated with no further development of opportunistic infections. All pts refusing therapy and lost to follow-up were IVDUs. In conclusion, pts with GCT can be offered standard oncological therapy with similar results to those of the normal population but antiretroviral therapy should also be applied in a combined approach to better control the underlying HIV infection.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Antineoplastic Agents, Combined/*THERAPEUTIC USE AIDS-Related Complex/*COMPLICATIONS Bleomycin/ADMINISTRATION & DOSAGE Cisplatin/ADMINISTRATION & DOSAGE Dysgerminoma/*COMPLICATIONS/PATHOLOGY/RADIOTHERAPY/*THERAPY Etoposide/ADMINISTRATION & DOSAGE Follow-Up Studies Hemophilia/COMPLICATIONS Homosexuality Human HIV Infections/*COMPLICATIONS Lymph Node Excision Male Neoplasm Staging Neoplasms, Germ Cell and Embryonal/*COMPLICATIONS/PATHOLOGY/ RADIOTHERAPY/*THERAPY Substance Abuse Testicular Neoplasms/*COMPLICATIONS/PATHOLOGY/RADIOTHERAPY/ *THERAPY ABSTRACT
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
